Piramal Pharma Solutions expands in-vitro biology capabilities at Ahmedabad

Piramal Pharma Limited’s Pharma Solutions (PPS) business, a leading Contract Research, Development and Manufacturing Organisation (CDMO), has made a multimillion dollar investment to create a world-class highthroughput screening facility that will augment the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad. This new expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site. The benefits of this new investment will be seen in an improved experience for PPS discovery services customers. With integrated chemistry and biology services now available from a single site, we anticipate significant improvements to drug discovery cycle times. In addition, new personnel with experience in biology services are being added to the site team, complementing the existing technical and operational expertise.